Nachrichten zur Eli Lilly & Co. Aktie

JPMorgan resets LLY stock target on drug demand

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one…

Stocks Look Shaky, But This Sector is Booming (Biotech)

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.…

Is It Too Late to Buy Eli Lilly?

The stock has soared 400% in recent years.…

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

Eli Lillys next leg of growth may have less to do with how well its weight loss drugs work and…

Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?

Shares of Eli Lilly have risen by over 40% since the company last reported earnings.…

Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the…

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.…

Top Stock Reports for Eli Lilly, HSBC & Palantir

Eli Lilly, HSBC and Palantir headline Zacks latest top stock reports, highlighting growth drivers, opportunities and key risks shaping each…

Lilly quietly hands Chinese partner its cancer drug

Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its…

House committee investigates Merck, AbbVie over China trials

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China…

OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCRs David Bautz

NASDAQ: MTVAGreg Young: Hello and welcome to the Life Sciences Investor Forum. On behalf of OTC Markets and our co-host,…

Can Eli Lillys New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term…

Ranking Wall Streets Trillion-Dollar Stocks From Most to Least Attractive, Based on Future Cash Flow

Among Nvidia, Apple, Alphabet, Microsoft, Amazon, Taiwan Semi, SpaceX, Broadcom, Tesla, Meta, Micron, Eli Lilly, and Berkshire Hathaway, there are…

Medicare will start covering obesity drugs for the first time. Heres what patients should know

The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that…

5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX

SpaceX recently completed a record IPO.…

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC…

Medicare deckt ab Juli GLP-1 Präparate von Eli Lilly ab! Morgan Stanley erhöht Marktvolumen auf 190 Mrd. USD!

Meilenstein in den USA: Ab Juli 2026 erhalten Mio. Senioren über das Medicare-Bridge-Programm Zugang zu GLP-1-Präparaten für nur 50…

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the…

Why Eli Lilly Gained 7% On Friday

…

Eli Lilly Leads 5 Stocks Near Buy Points As Market Rally Rotates

The top stocks are showing relative strength. Two are defensive growth plays.…

Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy?

Eli Lilly holds a dominant market share in the weight loss treatment category.…

Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more

Here are the companies making headlines in midday trading.…

Market movers: Triller Group, Eli Lilly, Onsemi…

…

Eli Lilly shares rise after EU panel backs expanded use of Jaypirca

Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agencys Committee for Medicinal Products…

Analysis-Hims obesity drug business may get boost as employers drop coverage

NEW YORK, June 25 (Reuters) - Telehealth provider Hims and Hers Health may get a boost next year from employers…

Hims obesity drug business may get boost as employers drop coverage

Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like…

Eli Lilly dives into hair loss treatments with investment in AI startup Absci

Eli Lilly is investing in a small startup developing a medication to spur hair growth, and potentially also treat endometriosis.…

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could…

Lillys 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?

Eli Lillys spate of acquisitions is building out multiple areas of its pipeline at once.…

3 Reasons to Buy Eli Lilly Stock

Despite several setbacks over the past year, the drugmaker marches on.…

Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Heres What That Means for Both Stocks.

These companies dont typically compete directly with one another, but that might change soon.…

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

These two healthcare leaders have a long history of competing against one another.…

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.…

3 Reasons to Buy Eli Lilly Stock Like Theres No Tomorrow

Eli Lilly is winning the GLP-1 race right now, but it isnt resting on its laurels.…

Eli Lilly: The Macro Health Crisis Is Still Undervalued

…

Drugmakers race to find a place in the next wave of obesity drugs

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.…

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the…

Mainzer Ministerpräsident sucht Verbündete für Erhalt von Pharmastandort

MAINZ (dpa-AFX) - Ministerpräsident Gordon Schnieder (CDU) sorgt sich um den Pharmastandort Rheinland-Pfalz. "Die Pharmawirtschaft ist…

Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the…

Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible…

Eli Lilly: Bears Are Missing The Underlying Thesis

…

Can Eli Lillys Clinical Momentum Keep the Stock at Record Highs?

LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering…

Eli Lilly stärkt GLP-1-Führungsanspruch – Foundayo übertrifft orales Semaglutid!

Eli Lilly treibt sein Wachstum durch die globale Dominanz im Markt für Inkretin-Medikamente mit Mounjaro und Zepbound voran. Phase-3-Daten…

Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?

Infectious disease could fuel Eli Lillys next growth phase.…

dpa-AFX ProFeed